DHA-PQP dispersible

Alfasigma

Product category
  • Artemisinin-based Combination Therapy (ACT)

  • Dihydroartemisinin-piperaquine

Therapeutic indication
  • Treatment of uncomplicated P. falciparum malaria in children and infants >5kg
Dosing
  • Once-daily for 3 days

Efficacy
  • Efficacy in adults established. PK bridging strategy to establish paediatric dose
Key features
  • Anticipated comparatively long post-treatment protection

Challenges
  • Cardiac monitoring restrictions 

  • Confirmed piperaquine resistance in Greater Mekong Sub-region (GMS)

Status
  • Pharmacokinetic studies in children completed 

  • Dossier under development for submission to EMA

Next milestone
  • Submission to EMA 

MMV Project Director
  • Adam Aspinall

* ACPR = adequate clinical and parasitological response